Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare

Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.

Authors

Institutions

Publication Details

Journal
The American Journal of Bioethics
Published
2025-02-23
DOI
https://doi.org/10.1080/15265161.2025.2457713
Citations
21
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
24.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare

Kelly E. Ormond, Marsha Michie, Karen M. Meagher, Yvonne Bombard et al.
21 citations
The American Journal of Bioethics
Biomedical Ethics and Regulation
24.45
article

Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare

Kelly E. Ormond, Marsha Michie, Karen M. Meagher, Yvonne Bombard, Kiran Musunuru, Kirsten A. Riggan, Megan A. Allyse, Rosario Isasi, Jane Q. Yap, Assata Kokayi, Roel Feys, Preya Agam, McKenna Horstmann
article en
21 citations

Abstract

Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.

The American Journal of BioethicsVol. 25(6)
University of Miami (US), University of Toronto (CA), WinnMed (US), ETH Zurich (CH), California University of Pennsylvania (US), Case Western Reserve University (US), Stanford University (US)
Openalex Percentile: Top 0%
Biomedical Ethics and Regulation
24.45
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.